Partner, SR One
Brian established the SR one Boston office in 2010 and is focused on building innovative therapeutic and life science companies. He previously led the firm’s investments in Dicerna Pharmaceuticals (NASDAZ: DRNA) and SpringLeaf Therapeutics. He has over 15 years of investing, business development, operational and R & D experience in both biotechnology and large pharma companies. He joined SR One from Sirtris Pharmaceuticals where he was responsible for corporate development, operations and post-merger integration following the $720M acquisition of Sirtris by GlaxoSmithKline in 2008. Prior to Sirtris, Brian was with Alantos Pharmaceuticals where he played key roles in the R & D and business development activities, and led many aspects of the post-merger integration following the $300M acquisition of Alantos by Amgen in 2007. Brian began his career in R & D at the Japanese pharma Eisai where he was a group leader for multiple programs in the oncology and inflammation/immunology therapeutic areas. He is an inventor on over twenty-five patents and patent applications, and is the senior author of a number of scientific publications. He currently serves on the Industry Advisory Boards for NYU Medical School and the National Brain Tumor Society, as a mentor for MassBio MassCONNECT, and as a peer reviewer/editorial board member for numerous journals and research funding authorities. Brian received his BS in Chemistry from the University of Massachusetts where he was a Shapiro scholar and his MS and PhD degrees in Organic Chemistry from the University of Michigan.